ClinicalTrials.gg
RecruitingNCT05071222ARTEGENEUpdated Mar 27, 2026

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)

A Phase 1/2 interventional study of ARTEGENE drug product in Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged Up to 47 Months. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
Up to 47 Months
Sex
All
01

Study summary

The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the severe combined immunodeficiency (SCID) caused by mutations in the human DCLRE1C gene (Artemis) by transplantation of a single dose of autologous CD34+ cells transduced ex vivo with the G2ARTE lentiviral vector expressing the DCLRE1C cDNA.

02

Conditions studied

  • Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency

Keywords

  • Artemis deficient Severe Combined Immunodeficiency
  • Severe Combined Immunodeficiency
  • Gene therapy
  • Allogeneic hematopoietic stem cells transplantation
03

In context

Severe Combined Immunodeficiency

59 studies on the registry are indexed under Severe Combined Immunodeficiency; 14 are open to participants now.

This study's planned enrollment of 7 is below the median of 10 across 31 interventional studies indexed under Severe Combined Immunodeficiency.

Browse Severe Combined Immunodeficiency studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 47 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient to 47 months
  • SCID patients with confirmed biallelic mutations in the Artemis (DCLRE1C) gene even in the case of leaky forms characterised by a residual activity
  • Absence of an HLA genoidentical donor or without rapidly available HLA-compatible unrelated donor (within six weeks of diagnosis)
  • The patient can be treated by gene therapy without delay in case of active life threatening infections compromising the short-term prognosis and for which the delay in finding a phenoidentical donor is incompatible with the patient's condition of health. Active life threatening infections are defined as: viral respiratory infection, CMV infection, adenovirus infection, disseminated BCGitis or other infections grade ≥ 4 according to scale
  • Beneficiary of a social security scheme
  • Parental, guardian's patient signed .

Exclusion criteria

Exclusion Criteria

  • Unwillingness to return for follow-up during the first 2 years study and the long term follow-up
  • -1 or 2 or HTLV1 infections
  • to G-CSF, busulfan or Fludarabine
  • Unable to tolerate general anesthesia and/or marrow harvest or peripheral blood stem cell collection (apheresis) or insertion of central venous catheter.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    ARTEGENE drug product

    Autologous purified CD34+ cells transduced with a self-inactivated lentiviral vector, expressing the DCLRE1C gene (alias Artemis)

    Genetic: ARTEGENE drug product

Interventions

  • GeneticARTEGENE drug product

    Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.

06

What researchers measure

Primary outcomes

  1. Incidence of transplant related mortality

    Time frame: Up to 100 days post treatment

  2. Incidence of transplant related mortality

    Time frame: At 6 months post treatment

  3. Transgene copy number on peripheral blood mononuclear cells (PBMCs)

    by qPCR

    Time frame: Up to 15 years post treatment

  4. Transgene copy number on sorted cell populations

    Determined on sorted cell populations CD15+,CD14+, CD19+, CD56+ and CD3+ T lymphocytes by qPCR

    Time frame: Up to 15 years post treatment

  5. Detection of replication-competent lentivirus (RCL)

    Time frame: 3 months post treatment

  6. Absence of any severe adverse events due to insertional mutagenesis

    Time frame: Up to 15 years post treatment

  7. Change in Artemis mRNA levels

    by RT-qPCR performed on the transduced CD34+ cells in the drug substance and on peripheral blood mononuclear cells (PBMC)

    Time frame: At Day 0, 12 months and 24 months post treatment

  8. Adverse events

    Frequency and severity of clinical AEs and changes in laboratory parameters

    Time frame: Up to 15 years post treatment

  9. Transgene copy number in the transduced CD34+ cells in the drug substance

    by qPCR

    Time frame: At Day 0

  10. Change in total number of T cells

    by flow cytometry

    Time frame: 6, 12, 24 months post treatment

  11. Change in distribution of different subpopulations

    by flow cytometry, according to the WBC count: Naïve and activated/memory CD4+ and CD8+ T cells will be evaluated using CCR7/CD45RA/CD45RO markers. Early thymic emigrants will be monitored by detecting CD31+CD45RA+CD4+ T lymphocytes; Stem cell-like memory CD8+ and CD4+ T cells will be quantified by counting CCR7+CD45RA+CD8+ T cells. Evaluation of the distribution of TCRαβ and TCRγδ T cells

    Time frame: 6, 12, 24 months post treatment

  12. Change in T lymphocyte in vitro proliferation in the presence of mitogens and antigens

    Time frame: 6, 12, 24 months post treatment

  13. Change in repertoire of T lymphocytes

    via high-throughput sequencing of the TCR

    Time frame: 12, 24 months post treatment

  14. Evaluation of the B lymphocyte compartment

    analysis of the circulating B cell subpopulations by flow cytometry: total CD19+ cells, naive (CD19+IgD+CD27-), switched memory (CD19+IgD-CD27+), marginal zone (CD19+IgD+CD27+), transitional (CD19+IgD+CD27-CD24highCD38+), 21low (CD19+CD38-CD21low). Immunoglobulin levels (IgG, A, M and E) and specific antibody production after immunization (if applicable)

    Time frame: 6 months post treatment

  15. Evaluation of the B lymphocyte compartment

    analysis of the circulating B cell subpopulations by flow cytometry: total CD19+ cells, naive (CD19+IgD+CD27-), switched memory (CD19+IgD-CD27+), marginal zone (CD19+IgD+CD27+), transitional (CD19+IgD+CD27-CD24highCD38+), 21low (CD19+CD38-CD21low). Immunoglobulin levels (IgG, A, M and E) and specific antibody production after immunization (if applicable)

    Time frame: At 12 months post treatment

  16. Evaluation of the B lymphocyte compartment

    analysis of the circulating B cell subpopulations by flow cytometry: total CD19+ cells, naive (CD19+IgD+CD27-), switched memory (CD19+IgD-CD27+), marginal zone (CD19+IgD+CD27+), transitional (CD19+IgD+CD27-CD24highCD38+), 21low (CD19+CD38-CD21low). Immunoglobulin levels (IgG, A, M and E) and specific antibody production after immunization (if applicable)

    Time frame: At 24 months post treatment

Secondary outcomes

  1. End of ongoing infection before the transplantation

    Time frame: Up to 15 years post treatment

  2. Kinetics of immune reconstitution

    Kinetics of immune reconstitution

    Time frame: Up to 15 years post treatment

  3. Adverse event

    Adverse event will be measured using CTCAE

    Time frame: Up to 15 years post treatment

07

Study locations

1 of 1 sites recruiting
  • Department of Pediatric Immunology, Hematology and Rheumatology UIHR, Necker-Enfants Malades Hospital
    Paris, 75015, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Nov 2041, 220 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Oct 8, 2021
StartActual
Jul 19, 2023
Primary completionEst.
Nov 19, 2041
CompletionEst.
Nov 19, 2041
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05071222
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Oct 8, 2021
Start date
Jul 19, 2023
Primary completion
Nov 19, 2041 (estimated)
Completion
Nov 19, 2041 (estimated)
Last update
Mar 27, 2026

Study contacts

Marina CAVAZZANA, MD, PhD
Contact
m.cavazzana@aphp.fr
+33 144495068
Jinmi BAEK, Master
Contact
jinmi.baek@aphp.fr
+33 1 42 19 28 49
Alessandra MAGNANI, MD, PhD
study director · Department of Biotherapy,LTCG, Necker-Enfants Malades Hospital
Chantal Lagresle-Peyrou, MD
study director · Imagine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion